Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy
Cet article décrit les modalités thérapeutiques susceptibles d'augmenter l'immunogénicité et l'antigénicité des cellules tumorales et passe en revue les stratégies thérapeutiques visant à renforcer la réponse immunitaire contre les tumeurs, en particulier les moyens d'induire le développement de structures lymphoïdes tertiaires, de renforcer la réponse des lymphocytes T cytotoxiques, de réduire le nombre de lymphocytes T régulateurs dans le microenvironnement tumoral et de favoriser l'acheminement des cellules immunitaires vers leur cible
Immune checkpoint blockade (ICB) have revolutionized medical oncology, with the occurrence of cures in situations regarded as palliative. However, most patients develop resistance and the selection of responders remains difficult. The search for predictive biomarkers for immunotherapy has revealed that tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) may be indicative of treatment effectiveness, since they may reflect the presence of an immune infiltrate with an anti-tumor effect. A better understanding of TLS neogenesis would help to establish anti-tumor strategies. For this purpose, this review outlines therapeutic modalities that could increase the immunogenicity and antigenicity of tumor cells, in particular immunogenic cell death (ICD), to turn ?cold? tumors in ?hot? tumors through interventions that promote the development of TLS. Second, the review describes the therapeutic strategies to enhance immune response against tumors, especially the resources to induce TLS, to strengthen cytotoxic T response / decrease Tregs and to promote the homing of immune cells. Future strategies should focus on a synergistic tactic combining both the enhancement of cancer cell immunogenicity and the stimulation of the immune system.
European Journal of Cancer , article en libre accès, 2025